Cannabidiol (CBD) is one of the main components of Cannabis sativa and has anxiolytic properties, but no study has been conducted to evaluate the effects of CBD on anxiety signs and symptoms in patients with Parkinson’s disease (PD). This study aimed to evaluate the impacts of acute CBD administration at a dose of 300 mg on anxiety measures and tremors induced by a Simulated Public Speaking Test (SPST) in individuals with PD.
Methods:
A randomised, double-blinded, placebo-controlled, crossover clinical trial was conducted. A total of 24 individuals with PD were included and underwent two experimental sessions within a 15-day interval. After taking CBD or a placebo, participants underwent the SPST. During the test, the following data were collected: heart rate, systemic blood pressure and tremor frequency and amplitude. In addition, the Visual Analog Mood Scales (VAMS) and Self-Statements during Public Speaking Scale were applied. Statistical analysis was performed by repeated-measures analysis of variance (ANOVA) while considering the drug, SPST phase and interactions between these variables.
Results:
There were statistically significant differences in the VAMS anxiety factor for the drug; CBD attenuated the anxiety experimentally induced by the SPST. Repeated-measures ANOVA showed significant differences in the drug for the variable related to tremor amplitude as recorded by the accelerometer.
Conclusion:
Acute CBD administration at a dose of 300 mg decreased anxiety in patients with PD, and there was also decreased tremor amplitude in an anxiogenic situation.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Washington, DC: American Psychiatric Press.
2.
ArjmandSVaziriZBehzadiM, et al. (2015) Cannabinoids and tremor induced by motor-related disorders: friend or foe?Neurotherapeutics12: 778–787.
3.
BarbosaMTCaramelliPMaiaDP, et al. (2006) Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord21: 800–808.
4.
BergamaschiMMQueirozRHCChagasMHN, et al. (2011a) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology36: 1219.
5.
BergamaschiMMQueirozRHZuardiAW, et al. (2011b) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf6: 237–249.
6.
BlessingEMSteenkampMMManzanaresJ, et al. (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics12: 825–836.
7.
BraakHDel TrediciK (2008) Nervous system pathology in sporadic Parkinson disease. Neurology70: 1916–1925.
8.
BroenMPGNarayenNEKuijfML, et al. (2016) Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord31: 1125–1133.
9.
BrownJDWintersteinAG (2019) Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. J. Clin. Med8(7): 989.
10.
CamposACGuimarãesFS (2008) Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology199: 223–230.
11.
CamposACFogaçaMVSonegoAB, et al. (2016) Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res112: 119–127.
12.
CamposACMoreiraFAGomesFV, et al. (2012) Multiple mechanisms involved in the large spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci367: 3364–3378.
13.
ChagasMHNOliveiraTHGFLinaresIMP, et al. (2017) Can anxiety increase tremors in patients with Parkinson’s disease? An experimental model. Eur Arch Psychiatry Clin Neurosci44: 85–88.
14.
ChagasMHNTumasVLoureiroS, et al. (2009) Does the association between anxiety and Parkinson’s disease really exist? A literature review. Curr Psychiatry Rev5: 29–36.
15.
ChagasMHNZuardiAWTumasV, et al. (2014) Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol28: 1088–1098.
16.
DaiHZhangPLuethT (2015) Quantitative assessment of parkinsonian tremor based on an inertial measurement unit. Sensors15: 25055–25071.
17.
DissanayakaNNO’SullivanJDPachanaNA, et al. (2016) Disease-specific anxiety symptomatology in Parkinson’s disease. Int Psychogeriatr1–11.
18.
DissanayakaNNWhiteEO’SullivanJD, et al. (2014) The clinical spectrum of anxiety in Parkinson’s disease. Mov Disord29: 967–975.
19.
DoderMRabinerEATurjanskiN, et al. (2003) Tremor in Parkinson’s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology60(4) 601–605.
FahnSEltonRL and members of the UPDRS development committee (1987) Unified Parkinson’s disease rating scale (UPDRS). In: FahnSMarsdenCDCalneDB, et al. (eds) Recent Developments in Parkinson’s Disease. Florham Park, NJ: Macmillan Health Care.
22.
Fusar-PoliPAllenPBhattacharyyaS, et al. (2010) Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol13: 421–432.
23.
García-ArencibiaMGarcíaCKurzA, et al. (2009) Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes. J Neural Transm Suppl73: 269–275.
24.
GibsonJD.What is the interpretation of spectral entropy? (1994) In: Proceedings of 1994 IEEE International Symposium on Information Theory, Trondheim, Norway, 27 June–1 July 1994, p. 440. Piscataway, NJ: IEEE.
25.
GomesFVResstelLBMGuimarãesFS (2011) The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology213: 465–473.
26.
GordonPHPullmanSLLouisED, et al. (2002) Mirtazapine in Parkinsonian tremor. Parkinsonism Relat Disord9: 125–126.
27.
HoehnMMYahrMD (1967) Parkinsonism: onset, progression and mortality. Neurology17: 427–442.
28.
HofmannSGDibartoloPM (2000) An instrument to assess self-statements during public speaking: scale development and preliminary psychometric properties. Behav Ther31: 499–515.
29.
HuiYPWangTHanLN, et al. (2015) Anxiolytic effects of prelimbic 5-HT(1A) receptor activation in the hemiparkinsonian rat. Behav Brain Res277: 211–220.
30.
HuotPFoxSH (2013) The serotonergic system in motor and non-motor manifestations of Parkinson’s disease. Exp Brain Res230: 463–476.
31.
JangWHanJParkJ, et al. (2013). Wave form analysis of tremor may help to differentiate Parkinson’s disease from drug-induced parkinsonism. Physiol Meas34: N15–N24.
32.
IfflandKGrotenhermenF (2017) An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res2: 139–154.
33.
LinaresIMZuardiAWPereiraLC, et al. (2019) Cannabidiol presents an inverted U-shaped dose–response curve in a simulated public speaking test. Braz J Psychiatry41: 9–14.
34.
McNairDMFrankenthalerLMCzerlinskyT, et al. (1982) Simulated public speaking as a model of clinical anxiety. Psychopharmacol77: 7–10.
35.
MarinusJZhuKMarrasC, et al. (2018) Risk factors for non-motor symptoms in Parkinson’s disease. Lancet Neurol17: 559–568.
36.
MillarSAStoneNLYatesAS, et al. (2018) A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol9: 1365.
37.
MoriyamaTSChagasMHNSilveira-MoriyamaL, et al. (2016) Diagnosing social anxiety in Parkinson’s disease: characteristics and frequencies according to two diagnostic criteria. Rev Psiquiatr Clín43: 139–142.
38.
NorrisH (1971) The action of sedatives on brain stem oculomotor systems in man. Neuropharmacol10: 181–191.
39.
OsórioFLCrippaJASLoureiroSR (2008) Self statements during public speaking scale (SSPS): cross-cultural adaptation for Brazilian Portuguese and internal consistency. Rev Psiquiatr Clín35: 207–211.
40.
PeresFFLimaACHallakJEC, et al. (2018) Cannabidiol as a promising strategy to treat and prevent movement disorders?Front Pharmacol9: 1–12.
41.
PisantiSMalfitanoAMCiagliaE, et al. (2017) Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther175: 133–150.
42.
PontiMBetPOliveiraCL, et al. (2017) Better than counting seconds: Identifying fallers among healthy elderly using fusion of accelerometer features and dual-task Timed Up and Go. PLoS one12: e0175559.
43.
PontoneGMWilliamsJRAndersonKE, et al. (2013) Pharmacologic treatment of anxiety disorders in Parkinson’s disease. Am J Geriatr Psychiatry21: 520–528.
44.
RuehleSReyAARemmersF, et al. (2012) The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol26: 23–39.
45.
RuizPJGBernardosVSBartoloméM, et al. (2007) Capit timed tests quantify age-related motor decline in normal subjects. J Neurol Sci260: 283–285.
46.
SagnaAGalloJJPontoneGM (2014) Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson’s disease. Parkinsonism Relat Disord20: 708–715.
47.
SchwabRSEnglandAC (1969) Projection technique for evaluating surgery in Parkinson’s disease. In: GillinghamFJDonaldsonMC (eds) Third Symposium on Parkinson’s Disease. Edinburgh, UK: Livingston, pp. 152–157.
48.
SunYNWangTWangY, et al. (2015) Activation of 5-HT1A receptors in the medial subdivision of the central nucleus of the amygdala produces anxiolytic effects in a rat model of Parkinson’s disease. Neuropharmacol95: 181–191.
49.
SvíženskáIDubovýPŠulcováA (2008) Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures – a short review. Pharmacol Biochem Behav90: 501–511.
50.
VriendCBoedhoePSWRuttenS, et al. (2016) A smaller amygdala is associated with anxiety in Parkinson’s disease: a combined FreeSurfer-VBM study. J Neurol Neurosurg Psychiatry87: 493–500.
51.
WileDJRanawayaRKissZH (2014) Smart watch accelerometry for analysis and diagnosis of tremor. J Neurosci Methods230: 1–4.
52.
ZuardiAWKarniolI (1981) Estudo Transcultural de uma Escala de Auto-avaliação para estados subjetivos. J Bras Psiquiatr31: 403–496.
53.
ZuardiAWCosmeRAGraeffFG, et al. (1993) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol7: 82–88.
54.
ZuardiAWRodriguesNPSilvaAL, et al. (2017) Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol8: 259.
